COVID-19 has brought us past the tipping point on the issue of health inequity. No doubt, health disparities linked to social determinants of health (SDOH) – such as race, gender, age, ethnicity, income and education level) – have existed since the dawn of the U.S. healthcare system. The pandemic has highlighted just how stark those disparities are, thrusting issues like clinical trial diversity, patient access and quality of care into the spotlight. 

With racial and ethnic minorities up to three times more likely than whites to be hospitalized with COVID-19 and twice as likely to die from it, America’s health inequity problem has become impossible to ignore. As we enter year three of the pandemic, the pressure is on to do better, with providers, payers and pharma alike mounting a response in hopes of making real progress. 

Health inequity is a persistent and pervasive issue with no silver-bullet solution. Making a difference will require multiple solutions from many stakeholders across the entire healthcare continuum; that much is clear. If yours is one of the organizations working on this issue – and most are in some capacity – what might not be quite so clear is where to start. That’s where data comes in.

You Can’t Manage What You Can’t Measure

The old adage about management and measurement certainly applies to health inequity. Before your organization can make an impact, you’ll need to understand where your patient population of interest stands today with regard to health disparities. You will also need a clearer picture of the connections between SDOH, disease burden and health outcomes, in all of their complexity. Only equipped with these insights will you truly be ready to take effective action in addressing root causes of inequity.

You might assume your organization needs a sophisticated data infrastructure to untangle the complex connections between SDOH, disease burden and health outcomes. But that’s no longer true. PurpleLab SDOH can help you overcome these barriers and get actionable health inequity insights. We use billions of data points so you can build a comprehensive patient population profile and gain transparency into current care practices and longitudinal patient journeys. Our SDOH data is insight-ready and exhaustive – which is key to tackling the many dimensions of health inequity. Just as importantly, the process of capturing both patient- and provider-level insights is simple for the everyday user.

Whether the goal is to expand market access, diversify clinical trials, or ensure equitable care delivery, the insights to help healthcare organizations pave a path forward on health inequity are readily accessible. We’re well past the tipping point. The healthcare ecosystem is aware that addressing health inequity is both the right thing to do and good for business. It’s time to move forward faster, together.

We use billions of data points to understand the complex relationships between SDOH variables, the burden of disease, and health outcomes. Life sciences and healthcare organizations are using our proprietary HealthNexus platform to understand health disparities to improve access to their novel treatments as well as increase the diversity of clinical trial populations. For more information, visit PurpleLab.com/SDOH.

SHARE THIS ARTICLE:

Recommended Articles

Life sciences companies would do both well and good to take advantage of the latest tools and platforms to understand the drivers of health inequity so that they can continue to root it out…

HCP segmentation can be a powerful tool for life sciences companies to target their best sales prospects—but historical data will only get you so far. Data that only looks back can be misleading, and a point-in-time snapshot can make it impossible to tell the difference between HCPs whose volumes are trending down and those who […]

Sales targeting is something medical devices companies definitely can’t afford to get wrong. Whether you’re at PMA (Premarket Approval) trying to maximize initial sales investments, or already in market and working to grow share, you need to get targeting right— right now.